Xiaobing Duan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaobing Duan has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Bo Zhu
Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
12 shared publications - Chaopin Yang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
12 shared publications - Guojun Liu
Shandong Qilu Stem Cell Engineering Co. Ltd., Shandong, P.R. China
12 shared publications - Haiwen Chen
State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, P.R. China
12 shared publications - Jiexia Zhang
Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
12 shared publications - Pingjuan Liu
Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
12 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
IS 26 -mediated circular bla KPC transposon in ST2483 Pseudomonas aeruginosa
The global spread of carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a critical clinical threat, with bla KPC as a key mobile carbapenem resistance gene. Here, we investigated a novel bla KPC-2 genetic element and its transmission in clinical ST2483 isolate PA100 via whole-genome sequencing, molecular, and phenotypic testing, and vesicle analysis. A unique 4,746-bp IS 26 -flanked structure inserted at the chromosomal InaA/pncB2 locus was confirmed, which forms a circular transposition intermediate through IS 26 recombination. PA100 exhibited ~40-fold higher bla KPC-2 copy number and ~25-fold higher mRNA expression vs chromosomal bla KPC-2 strain PA3; meropenem exposure further elevated its transcription by nearly 70-fold, far exceeding controls. PA100 showed an extensively drug-resistant phenotype with high-level carbapenem resistance, while remaining susceptible to ceftazidime-avibactam and cefiderocol. No classical conjugation or transformation was observed, while intact outer membrane vesicles (OMVs) from PA100 carried bla KPC-2 , supporting a non-plasmid, vesicle-associated route for transient delivery of the resistance gene under the tested conditions. The circular transposon remained genetically stable after 10 generations of passaging in PA100; however, stable maintenance in the PAO1 recipient was not detected after passage. In summary, we first report an IS 26 -driven circular bla KPC-2 transposon in ST2483 P. aeruginosa , conferring robust overexpression and stable inheritance in the donor strain, with OMVs potentially facilitating its horizontal spread, although stable maintenance in recipient cells was not demonstrated under the current assay conditions. These data advance understanding of bla KPC dissemination in CRPA and highlight clinical surveillance priorities for rare high-risk sequence types.
- 7 October 2026
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (10)
Open AccessIS 26 -mediated circular bla KPC transposon in ST2483 Pseudomonas aeruginosa
The global spread of carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a critical clinical threat, with bla KPC as a key mobile carbapenem resistance gene. Here, we investigated a novel bla KPC-2 genetic element and its transmission in clinical ST2483 isolate PA100 via whole-genome sequencing, molecular, and phenotypic testing, and vesicle analysis. A unique 4,746-bp IS 26 -flanked structure inserted at the chromosomal InaA/pncB2 locus was confirmed, which forms a circular transposition intermediate through IS 26 recombination. PA100 exhibited ~40-fold higher bla KPC-2 copy number and ~25-fold higher mRNA expression vs chromosomal bla KPC-2 strain PA3; meropenem exposure further elevated its transcription by nearly 70-fold, far exceeding controls. PA100 showed an extensively drug-resistant phenotype with high-level carbapenem resistance, while remaining susceptible to ceftazidime-avibactam and cefiderocol. No classical conjugation or transformation was observed, while intact outer membrane vesicles (OMVs) from PA100 carried bla KPC-2 , supporting a non-plasmid, vesicle-associated route for transient delivery of the resistance gene under the tested conditions. The circular transposon remained genetically stable after 10 generations of passaging in PA100; however, stable maintenance in the PAO1 recipient was not detected after passage. In summary, we first report an IS 26 -driven circular bla KPC-2 transposon in ST2483 P. aeruginosa , conferring robust overexpression and stable inheritance in the donor strain, with OMVs potentially facilitating its horizontal spread, although stable maintenance in recipient cells was not demonstrated under the current assay conditions. These data advance understanding of bla KPC dissemination in CRPA and highlight clinical surveillance priorities for rare high-risk sequence types.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Supplementary Figures and Tables
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
Supplementary Figures and Tables
- Open Access
- 25 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (11) , 3005-3025
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
Retinoic acid-inducible gene I (RIG-I) is a pattern recognition receptor involved in innate immunity, but its role in adaptive immunity, specifically in the context of CD8 + T-cell antitumour immunity, remains unclear. Here, we demonstrate that RIG-I is upregulated in tumour-infiltrating CD8 + T cells, where it functions as an intracellular checkpoint to negatively regulate CD8 + T-cell function and limit antitumour immunity. Mechanistically, the upregulation of RIG-I in CD8 + T cells is induced by activated T cells, and directly inhibits the AKT/glycolysis signalling pathway. In addition, knocking out RIG-I enhances the efficacy of adoptively transferred T cells against solid tumours, and inhibiting RIG-I enhances the response to PD-1 blockade. Overall, our study identifies RIG-I as an intracellular checkpoint and a potential target for alleviating inhibitory constraints on T cells in cancer immunotherapy, either alone or in combination with an immune checkpoint inhibitor.
- 25 September 2024
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 16 (11) , 3005-3025
Open AccessRIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
Retinoic acid-inducible gene I (RIG-I) is a pattern recognition receptor involved in innate immunity, but its role in adaptive immunity, specifically in the context of CD8 + T-cell antitumour immunity, remains unclear. Here, we demonstrate that RIG-I is upregulated in tumour-infiltrating CD8 + T cells, where it functions as an intracellular checkpoint to negatively regulate CD8 + T-cell function and limit antitumour immunity. Mechanistically, the upregulation of RIG-I in CD8 + T cells is induced by activated T cells, and directly inhibits the AKT/glycolysis signalling pathway. In addition, knocking out RIG-I enhances the efficacy of adoptively transferred T cells against solid tumours, and inhibiting RIG-I enhances the response to PD-1 blockade. Overall, our study identifies RIG-I as an intracellular checkpoint and a potential target for alleviating inhibitory constraints on T cells in cancer immunotherapy, either alone or in combination with an immune checkpoint inhibitor.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV+ NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV-positive NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. Based on our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated epithelial malignancy characterized by the presence of prominent infiltration of lymphocytes, including natural killer (NK) cells. Although NK cells can directly target EBV-infected tumor cells without restriction by the MHC, EBV+ NPC cells often develop resistance mechanisms that allow them to evade immune surveillance by NK cells. Elucidating the mechanisms involved in EBV-induced NK-cell dysfunction will contribute to the design of novel NK cell–based immunotherapies to treat NPC. Herein, we confirmed that the cytotoxic function of NK cells was impaired in EBV-positive NPC tissues and found that EBV infection–induced expression of B7-H3 in NPC negatively correlated with NK-cell function. The inhibitory effect of EBV+ tumor expression of B7-H3 on NK-cell function was clarified in vitro and in vivo. Mechanistically, activation of the PI3K/AKT/mTOR signaling pathway via EBV latent membrane protein 1 (LMP1) was responsible for EBV infection–induced upregulation of B7-H3 expression. In an NPC xenograft mouse model with adoptive transfer of primary NK cells, deletion of B7-H3 on tumor cells in combination with anti–PD-L1 treatment restored NK cell–mediated antitumor activity and significantly improved the antitumor efficacy of NK cells. Based on our findings, we conclude that EBV infection can inhibit NK cell–mediated antitumor function by inducing upregulation of B7-H3 expression and provide a rationale for NK cell–based immunotherapies in combination of PD-L1 blockade and overcoming the immunosuppression of B7-H3 to treat EBV-associated NPC.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Supplementary Figures and Tables
- 6 July 2024
- Published by EMBL-EBI
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
BioStudies – one package for all the data supporting a study
- 6 July 2024
- Published by EMBL-EBI
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
BioStudies – one package for all the data supporting a study
- 4 July 2024
- Published by EMBL-EBI
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
- 4 July 2024
- Published by EMBL-EBI
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
- 3 July 2024
- Published by EMBL-EBI
Source data of multiplex from IHC, HCC or colon cancer patients
BioStudies – one package for all the data supporting a study
- 3 July 2024
- Published by EMBL-EBI
Source data of multiplex from IHC, HCC or colon cancer patients
BioStudies – one package for all the data supporting a study
- 1 July 2024
- Published by EMBL-EBI
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
BioStudies – one package for all the data supporting a study
- 1 July 2024
- Published by EMBL-EBI
RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity
BioStudies – one package for all the data supporting a study